Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siliq in moderate to severe Hidradenitis Suppurativa
NCT04249713Phase 1Withdrawn
- Sponsor
- The Rockefeller University
- Start
- Feb 2020
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in hidradenitis suppurativa (HS), sponsored by The Rockefeller University. Primary endpoints: Biomarkers at Week 12, Biomarkers at Week 24 and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
brodalumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04249713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249713.